Targeting the HIF1α-HMOX1 axis could offer a novel approach to reducing osteocyte death and preserving bone integrity, thus improving the prognosis for melanoma patients with bone metastasis.

AXIS-SHIELD shares rose 42.5 to 545p yesterday, after the Anglo-Norwegian biotechnology company launched a new test for osteoporosis, the brittle-bone disease. The test determines whether patients ...

Six-axis technology is revolutionizing the treatment of bone deformities, offering a more accurate and efficient solution. Learn how this AI-aided system is changing the game for patients with ...